Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pharmacokinetic Study of Tesmilifene (YMB1002) Plus Epirubicin and Cyclophosphamide in Metastatic Breast Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
YM BioSciences
ClinicalTrials.gov Identifier:
NCT00364754
First received: August 15, 2006
Last updated: April 18, 2014
Last verified: April 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2006
  Primary Completion Date: January 2006 (Final data collection date for primary outcome measure)